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DMARD = disease modifying anti-rheumatic drug; GM-CSF = granulocyte macrophage colony-stimulating factor; IFN = interferon; IL = interleukin;
IL-1Ra = IL-1 receptor antagonist; IRAK = interleukin-receptor-associated kinase; NF-κB = nuclear factor- κB; RA = rheumatoid arthritis; Th = T
helper cells; TLR = toll-like receptor; TNF = tumor necrosis factor.
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Whereas TNFα antagonists provide impressive clinical
benefits in rheumatoid arthritis (RA), partial and non-
responder patients constitute residual unmet clinical need.
Establishing the therapeutic potential of individual
cytokines in rheumatoid arthritis, therefore, assumes
increasing importance. Rational choice of an appropriate
target however poses significant challenges as we move
from linear models of cytokine effector function in chronic
inflammation, to a ‘network concept’ of interacting
activities contributing in synergy across distinct tissue
events. In particular, cytokine mediated pathology may be
distinct in cartilage and bone as opposed to synovial
tissue or draining lymph node. For many given cytokines,
establishing tissue expression and local function is now
relatively straightforward. However, we believe that critical
decision making with respect to therapeutic utility remains
elusive. One must unravel functional pleiotropy and
redundancy for a cytokine, and explore patient variation in
expression and regulation prior to ‘rational’ progress.
IL-18, originally described as IFNγ inducing factor, is a
member of the IL-1 superfamily that includes IL-1α, IL-1β,
IL-1 receptor antagonist (IL-1Ra) and the recently
described IL-1F5-F10 cytokines [1,2]. Synthesised as an
23 kD pro-molecule (often pre-existing in resting
leukocytes), IL-18 is cleaved by caspase-1 to an active
18 kD ligand, that binds a heterodimeric receptor,
consisting of IL-18Rα and IL-18Rβ, that in turn mediates
signalling through the canonical IL-1R superfamily
signalling cascade that includes MyD88, IRAK (interleukin-
receptor-associated kinase) to NF-κB. IL-18 mRNA and
pro-protein are widely distributed, as are IL-18R
complexes suggesting an important role in early innate
immune responses. In vitro, IL-18 induces Th1 cell
maturation, migration and activation in synergy with IL-12
and IL-23, but can promote default Th2 differentiation of T
precursor cells even in the absence of IL-4 [2]. IL-18
activates and induces cytokine production by natural killer
cells, macrophages and neutrophils, promotes
angiogenesis and reverses endothelial cell apoptosis,
retards fibroblast apoptosis and modulates function in
varied tissue cell lineages including keratinocytes,
osteoclasts and chondrocytes [2]. Importantly, IL-18 often
acts in synergy rather than independently, and for some
activities it remains unclear whether direct or indirect
effects predominate. A further intriguing activity is the
potential to promote nociceptor function [3]. Numerous
recent  in vivo studies using both IL-18-gene-targeted
mice and neutralising agents such as anti-IL-18 antibody
or IL-18 binding protein, implicate IL-18 in components of
Commentary
Interleukin-18: a therapeutic target in rheumatoid arthritis?
Iain B McInnes, Foo Y Liew and J Alastair Gracie
Division of Immunology, Infection and Inflammation, University of Glasgow, UK
Corresponding author: Iain B McInnes, i.b.mcinnes@clinmed.gla.ac.uk
Published: 17 December 2004
Arthritis Res Ther 2005, 7:38-41 (DOI 10.1186/ar1497)
© 2004 BioMed Central Ltd
Abstract
Interleukin 18 (IL-18), a member of the IL-1 superfamily of cytokines has been demonstrated to be an
important mediator of both innate and adaptive immune responses. Several reports have implicated
its role in the pathogenesis of rheumatoid arthritis (RA). Although biologic therapy is firmly
established in the treatment of a number of inflammatory diseases including RA, partial and non-
responder patients constitute residual unmet clinical need. The aim of this article is to briefly review
the biology of, and experimental approaches to IL-18 neutralisation, together with speculation as to
the relative merits of IL-18 as an alternative to existing targets.
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host defence and in responses in autoimmune models of
disease [1,4–7], increasing interest in it as a therapeutic
target. Commensurate with the foregoing inflammatory
profile, IL-18 is subject to close regulation. Cleavage and
degradation of caspase-1 limits generation of active 18 kD
IL-18 prior to release mediated in part via P2X7
dependent pathways. In the extra cellular domain IL-18 is
antagonised by IL-18 binding protein and in part by
soluble IL-18Rα, although lower affinity binding of the
latter suggests it is a minor contributor.
We first reported IL-18 expression in RA synovial
membrane in macrophages, together with lining layer
fibroblasts. IL-18 promoted TNFα, IFNγ, granulocyte
macrophage colony-stimulating factor (GM-CSF) and
nitric oxide release in primary synovial cultures [8].
Osteoarthritis tissues, in contrast, exhibit virtually no IL-18
protein expression [8]. Several subsequent studies have
confirmed and extended these observations, in particular
in the intriguing observation that RA synovial IL-18
expression correlates not only with tissue TNFα and IL-1β
expression but also with erythrocyte sedimentation rate
[9,10]. Moreover, Bresnihan and colleagues correlated
synovial IL-18 expression with disease activity in
inflammatory arthritis following DMARD therapy [11].
Before treatment, tissue IL-18 expression correlated with
serum C reactive protein levels, but interestingly not with
serum IL-18. After DMARD treatment, there was
decreased tissue expression of IL-18 that correlated
significantly with change in serum IL-18 and C reactive
protein. The effects of IL-18 extend beyond T cell
activation. Recently, we have shown that IL-18 is an
important activator of synovial neutrophils [12]. Others
have demonstrated effects upon synovial fibroblast
activation, and on chemokine release [13–15] although
contradictory data have been reported [16].
In vivo observations further support a proinflammatory role
in articular inflammation. Thus, IL-18 can replace the
requirement for complete Freund’s adjuvant to induce
arthritis in collagen immunized DBA/1 mice [17]. Utilising
adenoviral delivery of IL-18 and TNFα/IL-1 deficient mice,
Joosten and colleagues subsequently demonstrated that
whilst IL-18-induced joint inflammation is independent of
IL-1, cartilage degradation requires IL-18 induced IL-1β
production [18]. Furthermore they suggest that TNF is
partly involved in IL-18-induced joint swelling and influx of
inflammatory cells, but cartilage proteoglycan loss occurs
independent of TNF. These findings indicate that IL-18, in
contrast to TNF, contributes through distinct pathways to
joint inflammation and cartilage destruction. IL-18-deficient
DBA/1 mice exhibit reduced incidence and severity of
collagen induced arthritis associated with amelioration of
articular damage [19]. Neutralisation of IL-18 by antibody
or IL-18 binding protein ameliorates collagen induced
arthritis [4,6] although the dose response of the latter is
unclear. IL-18 neutralisation also ameliorates strepto-
coccal induced arthritis. Moreover local overexpression of
IL-18 binding protein c by adenoviral delivery also
ameliorates articular destruction [5]. Thus, IL-18 is present
in the synovial lesion and is tractable in relevant in vivo
model systems.
Whereas the foregoing in vivo data suggest a pro-
destructive role, the effect of IL-18 in bone and cartilage
biology is controversial at this stage. Previous reports
have suggested that IL-18, independent of IFNγ, inhibits
osteoclast formation via increased production of GM-CSF
by T cells and osteoblasts [20,21]. However supporting
the notion that IL-18 facilitates bone destruction in RA, it
has been shown that IL-18 indirectly stimulates osteoclast
formation through upregulation of both soluble and
membrane bound RANKL (receptor activator of nuclear
factor κB ligand) by RA synovial derived T cells [22]. In
this study IL-18 stimulation failed to induce GM-CSF or
osteoprotegrin from T cells.
Several potential approaches to IL-18 targeting are
proposed [1,23,24]. Although synovial IL-18 expression
has been considered the primary target, expression
elsewhere in the circulation and in the lymphoid system
may also be therapeutically important – we recently
reported IL-18 expression in human lymph node, although
its function therein is unclear [25]. No consensus exists
to the optimal therapeutic modality. Generation of anti-
IL-18 monoclonal neutralising antibodies represents an
attractive approach, although at this time clinical studies
have not yet commenced. Antibody offers the potential to
select binding site and affinity to optimise therapeutic
neutralisation – this in turn may offer advantages midst
the complex milieu of regulatory pathways described for
IL-18. High affinity binding by IL-18 binding protein a and
c isoforms renders these obvious neutralising agents, and
early clinical studies to establish the safety of this
approach are in progress. Whether the dose response
will prove useful in clinical studies is however unclear. In
contrast, the lower affinity of native soluble IL-18Rα has
dissuaded use of this moiety thus far. Directly targeting
the IL-18R receptor, e.g. via antibody or specific
antagonist, is also of potential interest, although shared
utilisation with other IL-1 cytokines, e.g. IL-1F7, may
reduce the specificity of such an approach [26]. Small
molecule approaches include inhibitors of caspase-1,
antagonism of P2X7 receptors and generation of
inhibitors to components of the IL-18 receptor signalling
pathway. The latter approaches will provide limited
specificity for IL-18 since generation and release of other
IL-1 superfamily members may also be inhibited. Whether
this offers therapeutic disadvantage is however unclear
and need not be assumed. They provide potential
advantages in oral delivery, patient tolerance and cost in
the longer term.40
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Is IL-18 therefore a good therapeutic target in RA? IL-18
functions in synergy with numerous cytokines present
within the synovial compartment including IL-12 and IL-15
and as such it probably serves to amplify ongoing
inflammatory responses (‘adjuvant-like’). Blockade could
therefore usefully impinge on the optimal function of a
number of proinflammatory pathways therein. IL-18 also
apparently acts upstream of TNF release in some model
systems [18]. The foregoing offer likely therapeutic
advantage. However, whether the IL-18R signalling
pathway is sufficiently distinct from that of IL-1, which in
turn has proven disappointing as a target in clinical trials is
not yet clear. The effects of IL-1 and IL-18 in vitro are not
synonymous, e.g. IL-1 directly activates synovial fibro-
blasts and chondrocyte metabolism whereas IL-18
appears to operate via indirect means including IL-1 itself
[16,18]. This could reflect distinct receptor expression or
divergent signalling. Similarly, IL-18 has potent effects on
T lymphocyte maturation that are distinct from IL-1.
Nevertheless, toll-like receptor (TLR) dependent signals
have been shown to bypass IL-1 in serum transfer arthritis
[27] and it is possible that the IL-1R superfamily exhibits
too much functional redundancy to offer utility in practice.
As TLR signalling has unravelled, discrete functions have
emerged for distinct signalling pathways and adapter
moieties, offering opportunity for future, more specific
intervention [28]. IL-18 targeting also offers further
potential disadvantages. Infectious models in which IL-18
has been targeted or in IL-18 deficient mice clearly show a
role for this cytokine in host defence to bacterial and
fungal infection [2,29], although IL-18 function has not yet
appeared critical. At this stage IL-18 appears little
different from other cytokines targeted in RA – close
attention to the potential for infectious complications
should be anticipated in clinical development.
The foregoing discussion clearly indicates that IL-18 offers
potential as a therapeutic target in RA. Caution with
respect to effects on bone biology should be balanced
with the potential for broad anti-inflammatory effects within
and beyond the synovium. IL-18 overexpression has been
variously reported in psoriasis, pulmonary inflammatory
diseases, inflammatory bowel diseases, and various
tumours, and therapeutic utility likely extends to a range of
inflammatory conditions. We recently detected IL-18
expression in psoriatic arthritis synovium and demon-
strated that such expression is maintained despite three
months methotrexate therapy [30]. The balance of
evidence strongly supports progression into clinical
studies at this time – only these however will determine
whether improvement in disease activity can be achieved.
We believe that carefully designed proof-of-concept
studies are indicated to ensure that pathogenetically
useful information at least is obtained. Indeed one might
usefully consider this as we progress with a range of novel
therapeutic targets in RA.
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